Abstract 143MO
Background
We have recently demonstrated that current heavy smokers with >20 pack-year (PY) smoking history (median, 48.8, IQR, 31.6–57.0 PY) and non-heavy smokers (<20 PY; median, 11.4; IQR, 7.3–14.4 PY) have about 40- and 10-times higher risk of lung cancer, respectively (JAMA-Oncol. 2022; 8:1428–1437). In the current study, we examined the magnitude of the graded risk increase associated with PY of smoking among current smokers.
Methods
Of the 2505 community-dwelling older current smokers (mean age, 73 ± 5.7 years, 69% women, 17% African American) in the Cardiovascular Health Study (CHS), 1973 were never-smokers. The 532 current smokers were categorized based on PY smoking into: <20 (n = 95), 20–39 (n = 157), 40–59 (n = 181) and ≥60 (n = 94). Cause-specific HR (95% CI) for incident lung during 23 years of follow-up were estimated for the 4 groups (reference: never-smokers) based on Cox regression model, adjusting age, sex, race and competing risk of death.
Results
Incident lung cancer occurred in 0.5% of never smokers, and 5.0%, 14.6%, 17.7% and 16.0% of those with <20, 20–39, 40–59, and ≥60 PY smoking history, respectively. Compared with never smokers, cause-specific HRs (95% CIs) for incident lung cancer in the 4 groups with <20, 20–39, 40–59, and ≥60 PY smoking history were 9.73 (3.27–28.99), 30.33 (14.25–64.53), 42.97 (20.76–88.94), and 46.02 (20.08–105.48), respectively.
Conclusions
The risk of lung cancer among current smokers with <20 PY smoking for whom low-dose computed tomography screening is not recommended is high, but the risk was 3 and 4 times higher in those 20–39 and 40–59 PY, but plateaued for those with ≥60 PY. This study underscores the importance of smoking abstinence and early cessation.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
7MO - Sotorasib in <italic>KRAS</italic> G12C–mutated advanced non-small cell lung cancer (aNSCLC): Overall survival (OS) data from the global expanded access program (EAP study-436)
Presenter: Natalie Maimon
Session: Mini Oral 1
Resources:
Abstract
Slides
Webcast
8MO - Adagrasib (MRTX849) in patients with advanced/metastatic KRAS G12C-mutated non-small cell lung cancer (NSCLC): Preliminary analysis of mutation allele frequency
Presenter: Pasi Jänne
Session: Mini Oral 1
Resources:
Abstract
Slides
Webcast
Invited Discussant 7MO, 8MO and 143MO
Presenter: Navneet Singh
Session: Mini Oral 1
Resources:
Slides
Webcast
9MO - Profile of immunorecognition related markers including HLA-1 expression to predict response to immunocheckpoint inhibitors in non-small cell lung cancer
Presenter: Maria Saigi Morgui
Session: Mini Oral 1
Resources:
Abstract
Slides
Webcast
145MO - Updated survival, efficacy and safety of adjuvant (adj) atezolizumab (atezo) after neoadjuvant (neoadj) atezo in the phase II LCMC3 study
Presenter: David Carbone
Session: Mini Oral 1
Resources:
Abstract
Slides
Webcast
Invited Discussant 9MO and 145MO
Presenter: Fernando Lopez-Rios
Session: Mini Oral 1
Resources:
Slides
Webcast